HK$52.80-HK$0.15 (-0.28%)
Shanghai HeartCare Medical Technology Corporation Limited’s quoted price sits in the upper half of its reported 52-week range, 25.89% below the high.
Loading market information…
HKSE · 0314.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 03:58 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Sipai Health Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 53.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Sipai Health Technology Co., Ltd.’s next earnings report is currently expected on Mar 23, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sipai Health Technology Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sipai Health Technology Co., Ltd. is a Chinese enterprise specializing in medical technology and health management. Its business operations are diversified across three primary divisions: Specialty Pharmacy, Physician Research Assistance, and Health Insurance Services. The Specialty Pharmacy division manages a network of dedicated pharmacies and is also involved in the distribution of pharmaceutical products to drug manufacturers and other supply chain partners. Through its Physician Research Assistance segment, Sipai Health provides comprehensive site management organization (SMO) support to pharmaceutical firms and clinical research institutions. These services encompass a broad spectrum, including site identification and setup, patient acquisition and oversight, data and document handling, on-site logistical management of drugs and biosamples, and trial conclusion. Additionally, this segment offers specialized image management for clinical studies. The Health Insurance Services division functions as an intermediary, delivering brokerage solutions to various insurance providers. Established in 2014, the company's headquarters are situated in Guangzhou, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:30 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$52.80-HK$0.15 (-0.28%)
Shanghai HeartCare Medical Technology Corporation Limited’s quoted price sits in the upper half of its reported 52-week range, 25.89% below the high.
HK$2.36-HK$0.01 (-0.21%)
Chaoju Eye Care Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 25.0% below the high.
HK$3.12+HK$0.01 (+0.16%)
HighTide Therapeutics Inc’s quoted price sits in the lower half of its reported 52-week range, 34.0% below the high.
HK$0.93HK$0.00 (0.0%)
Rici Healthcare Holdings Limited’s quoted price sits in the upper half of its reported 52-week range, 25.0% below the high.
HK$0.92-HK$0.02 (-1.6%)
Dawnrays Pharmaceutical (Holdings) Limited’s quoted price sits in the lower half of its reported 52-week range, 26.4% below the high.
HK$0.16HK$0.00 (0.0%)
Town Health International Medical Group Limited’s quoted price sits in the lower half of its reported 52-week range, 44.41% below the high.
HK$2.00-HK$0.07 (-3.15%)
Zhaoke Ophthalmology Limited’s quoted price sits in the lower half of its reported 52-week range, 48.05% below the high.
HK$2.23-HK$0.01 (-0.22%)
JW (Cayman) Therapeutics Co. Ltd’s quoted price sits in the lower half of its reported 52-week range, 46.77% below the high.
